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Background. Genomic surveillance of methicillin-resistant Staphylococcus aureus (MRSA) identifies unsuspected transmission 
events and outbreaks. Used proactively, this could direct early and highly targeted infection control interventions to prevent ongoing 
spread. Here, we evaluated the cost-effectiveness of this intervention in a model that compared whole-genome sequencing plus cur-
rent practice versus current practice alone.
Methods. A UK cost-effectiveness study was conducted using an early model built from the perspective of the National Health 
Service and personal social services. The effectiveness of sequencing was based on the relative reduction in total MRSA acquisitions 
in a cohort of hospitalized patients in the year following their index admissions. A sensitivity analysis was used to illustrate and assess 
the level of confidence associated with the conclusions of our economic evaluation.
Results. A cohort of 65 000 patients were run through the model. Assuming that sequencing would result in a 90% reduction in 
MRSA acquisition, 290 new MRSA cases were avoided. This gave an absolute reduction of 28.8% and avoidance of 2 MRSA-related 
deaths. Base case results indicated that the use of routine, proactive MRSA sequencing would be associated with estimated cost sav-
ings of over £728 290 per annual hospitalized cohort. The impact in total quality-adjusted life years (QALYs) was relatively modest, 
with sequencing leading to an additional 14.28 QALYs gained. Results were most sensitive to changes in the probability of a MRSA-
negative patient acquiring MRSA during their hospital admission.
Conclusions. We showed that proactive genomic surveillance of MRSA is likely to be cost-effective. Further evaluation is re-
quired in the context of a prospective study.
Keywords. MRSA; cost-effectiveness; whole-genome sequencing.
Hospital outbreak detection is founded on principles used by 
John Snow during his investigation of a cholera epidemic [1]. 
Routine surveillance identifies patients who carry or are infected 
with specific pathogens, which are reviewed in relation to pa-
tient movement data and other information that could link 
cases. The identification of 2 or more patients positive for the 
same pathogenic species who are also linked in time and place 
triggers an assessment of the probability of an outbreak. In 
the case of bacterial pathogens, such as methicillin-resistant 
Staphylococcus aureus (MRSA), an assessment may incorpo-
rate routine data generated by the microbiology laboratory on 
antibiotic resistance. The pattern of resistance to the range of 
antibiotics tested in the laboratory is used as a surrogate for 
bacterial relatedness, although this lacks sensitivity and speci-
ficity. If the initial investigation concludes that an outbreak is 
possible or likely, formal typing methods may be used to define 
bacterial relatedness. Available typing methods lack sensitivity 
because of their low power to discriminate between isolates that 
reside in the same clone, and can erroneously link isolates that 
are not recently related [2–4]. Ultimately, the confirmation of 
an outbreak is based on a combination of imperfect evidence 
and the intuition of experienced infection control staff.
Whole-genome sequencing represents a major advance in the 
control of multidrug-resistant organisms (or other organisms) 
that spread between patients, units, and facilities. When 
combined with patient movement data, this provides a more 
accurate determination of transmission events and outbreak 
statuses than standard infection control methods alone [2–7]. 
An option for the uptake of bacterial sequencing into clinical 
practice is to simply swap the typing methods used during an 
outbreak investigation, but there would be several advantages of 
a process redesign in which sequencing was used proactively [8]. 
This would begin with the routine sequencing of specific bacte-
rial species of interest and the quantitation of genetic relatedness 
between isolates of the same species. Following sequencing, the 
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decision to investigate (or not) would be based on a desk-based 
analysis of the degree of relatedness, combined with informa-
tion on patient movements. This model would support efficient, 
highly targeted infection control interventions, provided that 
data can be generated rapidly and in a format that does not re-
quire specialist informatics knowledge. Early evidence for the 
potential benefits of this “Sequence First” approach came from 
a study of genomic surveillance of MRSA that was isolated in 
a large clinical microbiology laboratory in the east of England 
over 12 months [6]. This led to the identification of hundreds of 
transmission clusters that were not detected by standard infec-
tion controls. This highlights a missed opportunity for greater 
control through early outbreak detection, followed by action to 
minimize ongoing transmissions.
The potential value of genomic surveillance of nosocomial 
pathogens is compelling, but will result in an up-front cost. 
A rationale to support this cost is to align outbreak detection 
with other types of activity that relate to safety culture, which 
are fully justified on the basis that they save lives through pre-
vention, rapid detection, and effective action. However, evi-
dence of cost-effectiveness is often demanded of changes in 
healthcare practice.
METHODS
Model Overview
The aim of the model was to estimate the cost-effectiveness of 
whole-genome sequencing of MRSA combined with standard 
infection control practice, versus standard practice alone. A de-
cision tree framework (Figure 1) was used to estimate the re-
duction in the total number of MRSA acquisitions (including 
any subsequent infection) and, hence, the cost-effectiveness of 
whole-genome sequencing over 1 year, based on an annual co-
hort of newly admitted, hospitalized patients. Patients admitted 
to hospital or in high-risk specialties may be screened proactively 
Figure 1. Model schematic. Abbreviation: MRSA, methicillin-resistant Staphylococcus aureus.
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for carriage of MRSA, with additional MRSA testing occurring 
when clinical samples are taken to investigate patients with clin-
ical features of infection (or as part of an outbreak investigation). 
Patients within the model were classified as either MRSA-negative 
(as confirmed by a negative MRSA sample in some cases); 
MRSA-positive, asymptomatic (screening swab from a carrier); 
or MRSA-positive, infected (isolated from a clinical sample).
The model was built from the National Health Service (NHS) 
and personal social services perspective, which is consistent 
with the National Institute for Health and Care Excellence ref-
erence case [9]. As the model only estimated the cost-effective-
ness of whole-genome sequencing within 1 annual cohort of 
hospitalized patients, the discounting of costs and benefits was 
not necessary. Per-patient quality-adjusted life years (QALYs) 
were generated, and the primary outcome of the model was the 
incremental cost per QALY gained.
Data Sources and Model Parameters
Classification of Patients
Data generated during a 12-month prospective observa-
tional cohort study between April 2012 and April 2013 were 
used to inform patient classifications [6]. In brief, the Clinical 
Microbiology and Public Health Laboratory at the Cambridge 
University Hospitals NHS Foundation Trust processed samples 
from consecutive, MRSA-positive individuals. This facility re-
ceived samples from 3 hospitals and 75 general practices in the 
east of England. A total of 1465 MRSA-positive patients were 
identified, and 2282 MRSA isolates underwent whole-genome 
sequencing. For all MRSA-positive cases, epidemiological data 
(including hospital ward stays and residential post codes) were 
recorded. The catchment area from which the study patients 
were drawn contained a total of 5 012 137 residents, according 
to the 2011 UK census [6].
Effectiveness Inputs
The effectiveness of whole-genome sequencing was based on 
the relative reduction in the total number of MRSA acquisitions 
that occurred in a cohort of hospitalized patients in the year fol-
lowing their index admissions. The number of annual MRSA 
acquisitions expected within current practice (with data from 
the 12-month observational cohort study used as a proxy) was 
multiplied by the relative reduction to estimate the reduction 
in the number of MRSA acquisitions following whole-genome 
sequencing implementation. Due to a lack of published data to 
date, the likely size of this relative reduction of MRSA acquisition 
is hypothetical (Table 1). The probability of a MRSA-negative pa-
tient acquiring MRSA whilst in hospital was assumed to be 0.5%, 
in lieu of forthcoming data from an ongoing clinical evaluation 
at Cambridge University Hospitals. To explore the implications 
of these assumptions on the cost-effectiveness of whole-genome 
screening, both inputs were varied in the sensitivity analyses.
Methicillin-resistant Staphylococcus aureus–related Mortality
Within the early model, we assumed that 4.6% of all sympto-
matic, infected MRSA inpatients (involving any site or organ) 
would die of MRSA-related causes before their hospital dis-
charge (Table 1). This value came from a retrospective analysis 
of US National Inpatient Sample data from 2010 to 2014, where 
Table 1. Model Inputs
Patient Classification Parameters (%)
 Percentage of patients that undergo MRSA screening on admission 87.5 Cambridge University Data
 Proportion of patients MRSA positive following screening 1.1 Cambridge University Data
 Proportion of patients MRSA positive not screened 1.1 Assumed equal to above due to an absence of data 
  Probability MRSA-positive patient has symptomatic MRSA versus  
asymptomatic MRSA
14.1 Cambridge University Data
Effectiveness inputs (%)
  Probability of MRSA-negative patient acquiring MRSA during their stay (CP) 0.5 Assumption
 Reduction in MRSA acquisition due to genome sequencing 90 Assumption
Quality of life and mortality inputs
 Quality of life decrement associated with symptomatic MRSA 0.35 US decision analytic model [19]
  Proportion of symptomatic MRSA patients that die before discharge  
due to MRSA infection (%)
4.6 US cost study [10]
 Proportion of asymptomatic MRSA patients that die before discharge  
due to MRSA colonization (%)
0 Assumption
Costs inputs (£)
 Cost per case of symptomatic MRSA 17 238 Kunori et al [12]
 Cost per case of asymptomatic MRSA 386.80 Canadian decision tree [11]
 Cost per genome sequenced 100 A descriptive study of WGS for MRSA [4]
 Cost per screen positive 8.19 UK model. Robotham et al [14]
 Cost per screen negative 4.79 UK model. Robotham et al[14]
 Cost per clinical sample 3.62 UK model. Robotham et al [14]
Abbreviations: CP, current practice; MRSA, methicillin-resistant Staphylococcus aureus; WGS, whole-genome sequencing.
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358  140 MRSA-related hospitalizations were recorded [10]. 
Consistent with the previous literature [11], we assumed that 
colonized patients with no infection faced no MRSA-associated 
mortality risk.
Costs
We identified only 1 economic evaluation from a targeted lit-
erature search of MRSA surveillance and screening strategies 
in the United Kingdom, which reported the cost of a MRSA-
infected patient when admitted to an intensive care unit [12]. 
However, they did not report the cost of colonization, and we 
used a Canadian paper as the source for this parameter [11]. 
The paper reported the cost per case of positive, asymptomatic 
MRSA colonization in Canadian dollars, which was converted 
into British pounds using the exchange rate in 2010. A unit cost 
of £100 per genome sequenced was used in the base case anal-
ysis [4]. The costs to screen a patient for MRSA on admission 
to hospital, and for a clinical sample to be taken to investigate 
patients with clinical features of infection (as part of an outbreak 
investigation), were both taken from the NHS Scotland MRSA 
Screening Pathfinder Programme [13] (reported in Robotham 
et al [14]). All unit costs used within the economic model were 
inflated to the 2017/18 price year using the most recent Pay and 
Prices Index within the Personal Social Services Research Unit 
[15] and are presented in Table 1.
Health-related Quality of Life 
We applied a health-related quality-of-life decrement of 0.35 
to patients within the symptomatic health state to generate 
lost QALYs (Table 1). As MRSA carriage is asymptomatic, it 
was assumed that there is no QALY decrement associated with 
MRSA-positive colonization without infection.
Sensitivity Analysis
A sensitivity analysis was used to illustrate and assess the level 
of confidence associated with the conclusions of our economic 
evaluation. Both 1-way (where input parameters are varied 1 by 
1 between plausible extremes) and 2-way (where more than 1 
parameter is varied at the same time) sensitivity analyses were 
conducted to assess the robustness of the overall results within 
the model and to quantify effects of uncertainty on the cost-ef-
fectiveness of whole-genome sequencing.
RESULTS
Clinical Outcomes
The clinical outcomes estimated within the early model are 
presented in Table 2. A cohort of 65 000 patients were run through 
the model (equating to the estimated number of annual admissions 
for Addenbrooke’s hospital between April 2012 and April 2013) [6]. 
Under the assumption that data from whole-genome sequencing 
would result in a 90% reduction in MRSA acquisition, 290 new 
MRSA cases were avoided (which includes asymptomatic carriage 
and clinical infection). This gave an absolute reduction of 28.8% 
and an avoidance of 2 MRSA-related deaths.
Economic Outcomes
Our base case results indicated that the use of routine, pro-
active MRSA sequencing would be associated with estimated 
cost savings of over £728  290 per annual, hospitalized co-
hort (Table 3). The difference in total QALYs between the 2 
patient cohorts was more modest, with sequencing leading 
to an additional 14.28 QALYs gained. The results were most 
sensitive to changes in the probability of a MRSA-negative pa-
tient acquiring MRSA during their hospital admission. The 
results were also sensitive to the proportion of MRSA-positive 
patients with a clinical infection at the time of presentation 
to hospital, and the relative reduction in cases of MRSA ac-
quisition due to actions taken in response to whole-genome 
sequencing data. Figure 2 presents threshold graphs illustrating 
the changes in incremental costs and MRSA carriage, as well 
as the clinical infection events avoided as these parameters are 
changed. The higher the probability of a MRSA-negative pa-
tient acquiring MRSA during their stay, the greater the MRSA 
events avoided and the more costs saved by MRSA sequencing. 
A greater cost saving was observed as the relative reduction in 
MRSA acquisitions due to the implementation of sequencing 
increased. See the Supplementary Materials for a further sen-
sitivity analysis.
Table 2. Clinical Outcomes per Annual Hospitalized Patient Cohort (N = 65 000)
Clinical Outcome WGS + CP CP
Incremental
Absolute Relative (%)
Number of patients with MRSA sequenced 715 0 715 1.10
Number of MRSA-negative patients that acquire a MRSA infectiona 5 45 −41 −90
Number of asymptomatic MRSA cases 614 863 −249 −28.8
Number of symptomatic MRSA cases 101 142 −41 −28.8
Number of MRSA-related deaths 5 7 −2 −28.8
As these clinical outcomes are dependent upon assumptions within the model, we would not expect them to be equal to the to the results presented in the aforementioned prospective, 
observational cohort study [6].
Abbreviations: CP, current practice; MRSA, methicillin-resistant Staphylococcus aureus; WGS, whole-genome sequencing.
aThis refers to patients who were MRSA negative upon admission to hospital.
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The 2-way sensitivity analysis presented in Figure 3 provides 
an overview of how the incremental cost-effectiveness ratio 
changes when the key drivers of the cost-effectiveness results 
are varied simultaneously. Whole-genome sequencing was 
estimated to be cost-effective in the majority of scenarios that 
have been presented. For example, sequencing was expected 
to be cost-effective as long as the effectiveness was over 30%, 
regardless of the probability that a MRSA-negative patient 
would acquire MRSA during their hospital admission. The 
effectiveness could drop to 10% and sequencing would still be 
expected to be cost-effective, as long as the probability that a 
MRSA-negative patient would acquire MRSA during their hos-
pital admission was over 0.4%.
DISCUSSION
Our model is the first to estimate the cost-effectiveness of rou-
tine whole-genome sequencing of MRSA as an infection con-
trol tool. This indicated that routine MRSA sequencing would 
Table 3. Economic Outcomes per Annual Hospitalized Cohort (N = 65 000)
Economic Outcomes WGS + CP (£) CP (£)
Incremental
Absolute (£) Percentage (%)
Costs
 Genome sequencing costs 71 466 0.00 71 466 100
 MRSA-related treatment costs 1 974 473 2 774 112 −799 639 −40
 Admission screening costs 274 462 274 462 0.00 0
 Outbreak investigation screening costs 39 108 39 083 24 0
 Clinical sampling costs 365 513 −148 −40
 Total cost 2 359 873 3 088 170 −728 297 −31
QALYs
 Total QALYS 64 965 64 950 14 0.02
 Incremental cost per QALY Less costly and more effective (dominant)
Abbreviations: CP, current practice; MRSA, methicillin-resistant Staphylococcus aureus; QALY, quality-adjusted life year; WGS, whole-genome sequencing.
Figure 2. Threshold graphs (cohort of 65 000 patients). A negative incremental cost illustrates whole-genome sequencing as cost saving. For example, a −£1 000 000 
incremental cost means whole-genome sequencing is £1 000 000 cheaper than current practice alone. Abbreviation: MRSA, methicillin-resistant Staphylococcus aureus.
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result in fewer MRSA cases (both carriage and clinical infec-
tion, involving any organ or body site), and have a small, pos-
itive impact on health-related quality-of-life on a per-patient 
basis (regardless of whether they have or are tested for MRSA). 
This technological application is also likely to be cost-saving, 
assuming the relative reduction in MRSA cases is 90%. Given 
this assumption, extensive sensitivity analyses supported our 
cost-saving conclusion, even with large reductions in key 
parameters.
MRSA screening policies, the prevalence of MRSA, patient 
characteristics, and infection control practices may vary between 
different hospitals in England, which limits the generalizability 
of the results. Despite this, sequencing remained cost-effective 
when this value was varied in a sensitivity analysis. It must also 
be noted that the cost-effectiveness of sequencing is dependent 
upon the prevalence of MRSA colonization in patients upon 
admission to hospital. A greater prevalence allows for a larger 
potential for the reduction in MRSA transmission and, hence, a 
greater benefit associated with sequencing.
Our analyses represent an early, exploratory model that 
contained several uncertainties in model parameter values. The 
prospective, observational cohort study was limited to critical 
care units, and so undersampled the population served by the 
diagnostic laboratory. This reduced the accuracy of the rates 
of nosocomial transmission and acquisition of MRSA. MRSA 
acquisition rates were varied in sensitivity analyses and did not 
change the cost-effectiveness conclusions of the model. We 
used a mortality rate of 4.6% for hospital patients who develop a 
MRSA infection, which represents a composite death rate from 
all-site infections. This was derived from a recent US study [10], 
and outcomes may differ in a UK setting. Furthermore, the 
case mix in this previous study may differ to our patient pop-
ulation; our patients had a very low rate of MRSA bacteraemia 
[16], which is associated with high mortality [17]. Estimating 
the baseline QALY of an average hospitalized patient was diffi-
cult because of the heterogeneity of the in-patient population 
as a whole, and we assumed that the health-related quality of 
life was equal across patients upon entry to a hospital. A sen-
sitivity analysis did not indicate health-related quality of life to 
be a key driver of the model results. It is also highly likely that 
we overestimated the cost per case of a MRSA infection, as cost 
data were based on a study that assumed all patients would be 
treated within intensive care. These data were used because of 
the lack of other viable sources from a UK setting [12], but a 
sensitivity analysis demonstrated that, even at a minimal cost, 
sequencing would still be cost-effective due to the costs saved 
through the reduction in colonized MRSA patients.
Figure 3. A 2-way sensitivity analysis (cohort of 65 000 patients). Abbreviations: MRSA, methicillin-resistant Staphylococcus aureus; NICE, National Institute for Health 
and Care Excellence.
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A previously published comparative effectiveness review 
of screening for MRSA indicated insufficient evidence to de-
termine the effectiveness of MRSA screening strategies [18]. 
This did not consider the effectiveness of screening combined 
with sequencing. A strength of our economic analysis is that it 
highlights specific data collection requirements of future pro-
spective studies that evaluate the impact and cost-effectiveness 
of proactive MRSA sequencing.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. 
Consisting of data provided by the authors to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the authors, 
so questions or comments should be addressed to the corresponding author.
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